Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).
VISTA PHARMACEUTICALS LTD. Financial Highlights
- Revenue: VISTA PHARMACEUTICALS LTD. reported revenue of ₹5.72 crore in FY26 vs ₹10.51 crore in FY25. It showed a decrease of 45.58% on a yearly basis.
- Operating Profit: VISTA PHARMACEUTICALS LTD. reported an operating loss of ₹16.15 crore in FY26 vs ₹5.29 crore in FY25. It showed a decrease of 205.29% on a year-on-year basis.
- Net Profit: VISTA PHARMACEUTICALS LTD. reported a net loss of ₹12.06 crore in FY26 vs ₹4.65 crore in FY25. It showed a decrease of 159.35% on a yearly basis.
VISTA PHARMACEUTICALS LTD. Quarterly Result Highlights
- VISTA PHARMACEUTICALS LTD. reported revenue of ₹0.03 crore in Mar 2026, compared with ₹2.51 crore in Dec 2025, representing a decrease of 98.80% on a quarter-on-quarter (QoQ) basis.
- VISTA PHARMACEUTICALS LTD. reported an operating loss of ₹7.77 crore in Mar 2026, compared with ₹3.28 crore in Dec 2025, representing a decrease of 136.89% on a quarter-on-quarter (QoQ) basis.
- VISTA PHARMACEUTICALS LTD. reported a loss of ₹5.86 crore in Mar 2026, compared with ₹2.32 crore in Dec 2025, reflecting a decrease of 152.59% on a QoQ basis.
- The earnings per share (EPS) of VISTA PHARMACEUTICALS LTD. stood at ₹0.79 during Mar 2026.